



HOUSTON, TX – June 2, 2021

**Yokogawa Corporation of America to Contribute Bioreactor Expertise to
the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)**

*Yokogawa will co-innovate with industry leaders to advance
biopharmaceutical development and manufacturing*

Yokogawa Corporation of America announces that the company has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) as an industry member. Yokogawa will contribute expertise in bioreactor process control and automation through interaction with universities, industry-leading researchers and other NIIMBL members.

As a result of the COVID-19 pandemic, the global biopharmaceutical market has been growing at an unprecedented rate, with significant investments being made in diagnostics, vaccine development, and medical devices to test and treat the coronavirus. These investments have driven demand for infrastructure in developing and manufacturing monoclonal antibody drugs and products that require mammalian cell bioreactor technologies, such as Yokogawa's BR1000 Advanced Control Bioreactor System.

“The first Yokogawa bioprocess portfolio product, the BR1000, released earlier this year, offers significant performance advantages over existing methods for biologics development and automation,” stated Kevin McMillen, President and CEO of Yokogawa Corporation of America. “The BR1000 automates lab-scale mammalian cell culture with highly accurate real-time monitoring and advanced process control.”

NIIMBL collaborates with industry experts on innovative manufacturing technologies that bring life-saving and life-enhancing products to the market faster and at reduced cost, while maintaining safety and efficacy. This engagement solves industry challenges and develops a highly-skilled biopharmaceutical workforce. NIIMBL membership connects Yokogawa with industry leaders to leverage the company's technological expertise.

For more information about Yokogawa's BR1000 Advanced Control Bioreactor System, please visit:
<https://www.yokogawa.com/solutions/products-platforms/life-science/bioreactor/br1000/>

About Yokogawa

Yokogawa provides advanced technologies and services in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, food, and water. Yokogawa addresses customer issues regarding increasingly complex production, operations management, and the optimization of assets, energy, and the supply chain with digitally-enabled smart manufacturing, enabling the transition to autonomous operations.

Founded in Tokyo in 1915, Yokogawa continues to work toward a more sustainable society through its 17,500 employees in a global network of 119 companies spanning 60 countries.

For more information, visit www.yokogawa.com.